Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: rationale and design

BACKGROUND: Ischemic stroke and other vascular outcomes occur in 10–20% of patients in the 3 months following a TIA or minor ischemic stroke, and many are disabling. The highest risk period for these outcomes is the early hours and days immediately following the ischemic event. Aspirin is the most c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Stroke
Autores principales: Johnston, S. Claiborne, Easton, J. Donald, Farrant, Mary, Barsan, William, Battenhouse, Holly, Conwit, Robin, Dillon, Catherine, Elm, Jordan, Lindblad, Anne, Morgenstern, Lewis, Poisson, Sharon N., Palesch, Yuko
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4412261/
https://ncbi.nlm.nih.gov/pubmed/23879752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijs.12129
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares